

# Opioids Immediate Release (IR) New To Therapy with Daily Quantity Limit Program Criteria

This program applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies.

#### This is a FlexRx standard and GenRx standard program.

Single Ingredient Agent(s)	Indication(s)
butorphanol <sup>a</sup>	Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Nasal spray	
Codeine <sup>a</sup>	Management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are
Tablet	inadequate
Dilaudid	Management of pain severe enough to require an opioid analgesic
(hydromorphone) <sup>a</sup>	and for which alternative treatments are inadequate
Tablet	
Liquid	
Levorphanol <sup>a</sup>	Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Tablet	
Meperidine	Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Tablet	
Solution	
Dolophine, Methadose	Management of pain severe enough to require daily, around-the-
(methadone) <sup>a</sup>	clock, long-term opioid treatment and for which alternative treatment options are inadequate
Tablet	
Soluble tablet	
Solution	
Concentrate	
Morphine <sup>a</sup>	Management of acute and chronic pain severe enough to require an
	opioid analgesic and for which alternative treatments are
Tablet	inadequate
Concentrate	
Solution	
Oxaydo, Roxybond, Roxicodone	Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
(oxycodone) <sup>a</sup>	
Capsule	
Tablet	
Solution	
Concentrate	
Opana	Management of acute pain severe enough to require an opioid
(oxymorphone) <sup>a</sup>	analgesic and for which alternative treatments are inadequate

## FDA APPROVED INDICATIONS AND DOSAGE<sup>4-39</sup>

MN\_CSReg\_Opioids\_IR\_NTT\_QL\_ProgSum\_07-01-2024v2

Tablet	
Nucynta (tapentadol)	Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients aged 6 years and older with a body
Tablet	weight of at least 40 kg.
<b>Qdolo</b> (tramadol)	Management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Oral solution	
Ultram <sup>a</sup> , Tramadol	Management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are
Tablet	inadequate
Combination Ingredient Agent(s)	Indication(s)
Apadaz, Benzhydrocodone/ acetaminophen	Short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Tablet	
Tylenol w/Codeine Acetaminophen/ codeine <sup>a</sup>	Management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate
Tablet Oral solution	
Fioricet w/Codeine (butalbital/ acetaminophen/ caffeine/codeine) <sup>a</sup>	Management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate
Capsule	
<b>Fiorinal w/Codeine</b> (butalbital/aspirin/ caffeine/codeine) <sup>a</sup>	Management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate
Capsule	
Trezix, Acetaminophen/ caffeine/ dihydrocodeine	Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Capsule, tablet	
Hydrocodone/ Acetaminophen <sup>a</sup>	Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Solution	
Lortab	Management of pain severe enough to require an opioid analgesic
(hydrocodone/ acetaminophen)	and for which alternative treatments are inadequate
Solution	

MN\_CSReg\_Opioids\_IR\_NTT\_QL\_ProgSum\_07-01-2024v2

News	Management of main account on any site of a main in
Norco	Management of pain severe enough to require an opioid analgesic
(hydrocodone/	and for which alternative treatments are inadequate
acetaminophen) <sup>a</sup>	
Tablet	
Hydrocodone/	Short-term management of acute pain severe enough to require an
Ibuprofen <sup>a</sup>	opioid analgesic and for which alternative treatments are
	inadequate
Tablet	
Nalocet,	Management of pain severe enough to require an opioid analgesic
Oxycodone/	and for which alternative treatments are inadequate
Acetaminophen,	
Primlev, Prolate	
-	
Tablet	
Solution	
Percocet	Management of pain severe enough to require an opioid analgesic
(oxycodone/	and for which alternative treatments are inadequate
acetaminophen) <sup>a</sup>	
Tablet	
oxycodone/	Management of pain severe enough to require an opioid analgesic
aspirinª	and for which alternative treatments are inadequate
<b>-</b>	
Tablet	
Oxycodone/Ibuprofen	Management of short term (no more than 7 days) acute to
oxycouone/ibupioren	moderate pain severe enough to require an opioid analgesic and for
Tablet	which alternative treatments are inadequate
pentazocine/	Management of pain severe enough to require an opioid analgesic
naloxone <sup>a</sup>	and for which alternative treatments are inadequate
haloxone	
Tablet	
Seglentis	Management of acute pain in adults that is severe enough to
(celecoxib/tramadol)	require an opioid analgesic and for which alternative treatments are
	inadequate
Tablet	
Ultracet	Management of acute pain severe enough to require an opioid
(tramadol/	analgesic and for which alternative treatments are inadequate
acetaminophen) <sup>a</sup>	
Tablet	
– generic available	

a – generic available

#### **CLINICAL RATIONALE**

The Centers for Disease Control and Prevention (CDC) guidelines define acute pain as pain with abrupt onset and caused by an injury or other process that is not ongoing. Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be needed.<sup>1</sup>

Use of tramadol or codeine containing products in pediatric patients has caused lifethreatening respiratory depression, with some of the reported cases occurring posttonsillectomy and/or adenoidectomy. Ultra-rapid metabolizers are at increased risk of life-threatening respiratory depression due to a CYP2D6 polymorphism. Use in children under 12 years of age is contraindicated for these products, and for those between the ages of 12 and 18 years when used for post-operative pain management following tonsillectomy and/or adenoidectomy.<sup>3</sup>

The CDC defines chronic pain as pain that continues or is expected to continue more than three months or past the time of normal tissue healing. When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids. The FDA modified labeling of ER/LA opioids, indicating they should be reserved for management of severe, continuous pain requiring daily, around-the-clock, long term opioid treatment. The CDC indicates ER/LA opioids should be reserved for severe, continuous pain and should be considered only for patients who have received immediate-release opioids daily for at least 1 week. Assessment should be done to determine if continued opioid therapy is needed.<sup>1</sup>

The American Society of Interventional Pain Physicians (ASIPP) 2017 Guideline for Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain states that there is similar effectiveness for long and short-acting opioids, with increased adverse consequences of long-acting opioids. Long-acting agents should only be used in the management of severe, intractable pain.

The guidelines recommend the following for the treatment of chronic non-cancer pain:<sup>2</sup>

- Initiating therapy with an opioid:
  - Complete a comprehensive assessment and document comprehensive history, general medical condition, psychosocial history, psychiatric status, and substance use history
  - Screen for opioid abuse, utilize prescription drug monitoring programs (PDMPs), and utilize urine drug testing (UDT) to identify opioid abusers, reduce opioid abuse, and potentially reduce doctor shopping. Utilize at initiation of therapy and to monitor adherence
  - Establish appropriate physical and psychological diagnoses prior to initiating therapy
  - A pain management consultation, for non-pain physicians, if use of chronic opioids is planned or in patients where the total daily dose will exceed the recommended CDC morphine equivalent therapy
  - Establish medical necessity prior to initiation or maintenance of opioid therapy based on average, moderate, or severe (≥4 on a scale of 0-10) pain and/or disability
  - Establish treatment goals of opioid therapy with regard to pain relief and improvement in function
  - Obtain a robust agreement prior to initiating and maintaining opioid therapy. Agreements reduce over-use, misuse, abuse, and diversion
- Assessing improvement:
  - Assess improvement based on analgesia, activity, aberrant behavior, and adverse effects. Clinicians should document at least a 30% improvement in pain or disability without adverse consequences
  - Therapy must be started with short-acting opioids and should be maintained with lose doses
  - Evidence of effectiveness is similar for long-acting and short-acting opioids with increased prevalence of adverse consequences of long-acting opioids

- Long-acting opioids in high doses are recommended only in specific circumstances with severe intractable pain that is not amenable to shortacting opioids or moderate doses of long-acting opioids
- Low dose should be considered up to 40 MME, 41-90 MME should be considered moderate dose, and greater than 91 MME as high dose
- Long-acting opioids should not be utilized for initial opioid therapy
- Monitor adherence via UDT and PDMP to identify patients who are noncompliant or abusing prescription or illicit drugs
- Chronic opioid therapy may be continued, with continuous adherence monitoring, and modified in conjunction with or after failure of other modalities of treatments.

The 2022 CDC guidelines for Prescribing Opioids for Pain recommend the following for prescribing opioids for acute, subacute, and chronic pain:<sup>1</sup>

- When to initiate or continue opioids for chronic pain:
  - Clinicians should maximize use of non-pharmacologic and non-opioid pharmacologic therapies prior to initiating opioid therapy as appropriate for the specific condition and patient
  - Clinicians should consider opioids only if expected benefits for both pain and function are anticipated to outweigh risks to the patients. Opioids should be combined with non-pharmacologic therapy and non-opioid pharmacologic therapy, as appropriate
  - Clinicians should establish treatment goals with all patients prior to starting opioid therapy for chronic pain. Goals should include realistic goals for pain and function, and how to discontinue therapy if benefits do not outweigh the risks. Clinicians should only continue therapy with opioids if there is clinically meaningful improvement in pain and function that outweigh the risks to patient safety
  - Clinicians should discuss the risks and realistic benefits of opioid therapy prior to starting and periodically during therapy
- Opioid selection, dosage, duration, follow-up, and discontinuation:
  - Clinicians should prescribe immediate release opioids instead of extended release/long acting opioids when starting opioid therapy for chronic pain
  - The lowest effective dose should be prescribed when opioids are started. Clinicians should use caution when prescribing opioids, should reassess evidence of benefits and risks when increasing doses to greater than or equal to 50 morphine milligram equivalents (MME)/day, and should avoid increasing doses to greater than or equal to 90 MME/day or carefully justify titrating to doses greater than or equal to 90 MME/day
  - Opioids for acute pain should be prescribed at the lowest effective dose of immediate release opioids and should be prescribed at a quantity no greater than necessary for the expected duration of pain. Three days or less will often be sufficient; more than seven days will rarely be needed
  - Benefits and risks should be evaluated within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalations. Benefits and risks of continued therapy should be evaluated every 3 months or more frequently
  - Clinicians should re-evaluate patients at higher risk for opioid use disorder (e.g., patients with mental health conditions or depression, patients with a history of substance abuse, history of overdose, taking more than 50 MME/day, or taking other central nervous system depressants with opioids) more frequently than every 3 months
- Assessing Risk and addressing Harms of Opioid use:
  - Clinicians should incorporate into the management plan strategies to mitigate risk, including offering naloxone when there is increased risk of

opioid overdose, such as history of overdose, history of substance abuse disorder, higher opioid dosages ( $\geq$ 50 MME/day), or concurrent benzodiazepine use

- Patient's history of controlled substance use should be reviewed by the clinician using state prescription drug monitoring program (PDMP) data to determine if the patient is receiving opioid dosages or dangerous combinations that put the patient at high risk for overdose. PDMP data should be reviewed when starting opioid therapy for chronic pain and periodically during opioid therapy, ranging from every prescription to every 3 months
- Clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription and illicit drugs
- Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible

The CDC guideline for opioid prescribing note that patients with cancer, sickle cell disease, and patients receiving palliative or end of life care are exempt from these recommendations. The guidelines also states that although identification of an opioid use disorder can alter the expected benefits and risks of opioid therapy for pain, patients with co-occurring pain and substance use disorder require ongoing pain management that maximizes benefits relative to risks. Clinicians should continue to use non-pharmacologic and non-opioid pharmacologic pain treatments as appropriate and consider consulting a pain specialist as needed to provide optimal pain management.<sup>1</sup>

## References

- Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2022. MMWR Recomm Rep 2022;71(No. RR-3):1-95. Accessed at: https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm.
- 2. Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. *Pain Physician* 2017;20:S3-S92.
- 3. FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. April 2017.
- 4. Acetaminophen/caffeine/dihydrocodeine prescribing information. Atland Pharmaceuticals, LLC. January 2021.
- 5. Acetaminophen/codeine solution prescribing information. Akorn. November 2022.
- 6. Apadaz prescribing information. KVK Tech Inc. March 2021.
- 7. butorphanol tartrate nasal solution prescribing information. Apotex Corp. September 2023.
- 8. codeine prescribing information. Hikma Pharmaceuticals USA Inc. February 2023.
- 9. Dilaudid prescribing information. Purdue Pharma LP. January 2023.
- 10. Reference no longer used.
- 11. Fioricet with Codeine prescribing information. Actavis Pharma, Inc. March 2021.
- 12. Butalbital, Aspirin, Caffeine, Codeine Breckenridge Pharmaceutical. April 2021.
- 13. Hydrocodone/Acetaminophen 300 mg prescribing information. Alvogen Inc. December 2021.
- 14. Hydrocodone/Acetaminophen oral solution prescribing information. Eywa Pharma Inc. October 2022.
- 15. hydrocodone/ibuprofen prescribing information. Amneal Pharmaceuticals, LLC. November 2022.
- 16. levorphanol prescribing information. Lannett Company, Inc. January 2022.

- 17. Lortab prescribing information. Akorn, Inc. September 2022.
- 18. meperidine prescribing information. West-Ward Pharmaceuticals Corp. December 2022.
- 19. methadone prescribing information. VistaPharm, Inc. September 2021.
- 20. Methadose prescribing information. SpecGX, LLC. July 2021.
- 21. morphine prescribing information. Hikma Pharmaceuticals USA Inc. April 2022.
- 22. Hydrocodone/Acetaminophen tablet prescribing information. Amneal Pharmaceuticals, LLC. November 2022.
- 23. Nucynta prescribing information. Collegium Pharm, Inc. July 2023.
- 24. Oxaydo prescribing information. Zyla Life Sciences US Inc. July 2023.
- 25. oxycodone prescribing information. ANI Pharmaceuticals Inc. August 2021.
- 26. Oxycodone/acetaminophen 300 mg prescribing information. FH2 Pharma LLC. April 2023.
- 27. Oxycodone/acetaminophen 5/325 solution prescribing information. Nostrum Laboratories, Inc. September 2021.
- 28. Reference no longer used.
- 29. Reference no longer used.
- 30. oxymorphone prescribing information. Endo Pharmaceuticals. April 2023.
- 31. Pentazocine/naloxone prescribing information. Actavis Pharma, Inc. July 2020.
- 32. Percocet prescribing information. Endo Pharmaceuticals Inc. July 2022.
- 33. Prolate prescribing information. Forte Bio-Pharma LLC. September 2021.
- 34. Qdolo prescribing information. Athena Bioscience, LLC. September 2021.
- 35. Roxicodone prescribing information. Specgx LLC. January 2023.
- 36. Seglentis prescribing information. Kowa Pharmaceuticals America, Inc. October 2021.
- 37. Trezix prescribing information. Wraser Pharms LLC. February 2021.
- 38. Tylenol with codeine prescribing information. Janssen Pharms. October 2019.
- 39. Ultracet prescribing information. Jassen Pharma. February 2023.
- 40. Ultram prescribing information Janssen Pharms. February 2023.
- 41. Roxybond prescribing information. Protega Pharms. March 2021.

# **Opioids IR New To Therapy (Includes IR, ER, and Oncology) with Daily Quantity Limit**

## OBJECTIVE

The program will check if a patient is new to opioid therapy as defined as having no prior opioid use in the past 120 days. If the patient is new to therapy, the patient will be restricted to <50 MME per day and  $\leq$ 7 days of therapy. The program will allow for exceptions for uses beyond these limits based on program requirements. The program will also check for appropriate age for requests for products containing tramadol, dihydrocodeine, and codeine. Requests for these agents will be limited to patients 12 years of age and older, and patients 12 to 18 years will be restricted from use for post-operative pain management following a tonsillectomy and/or adenoidectomy. (program applies to all Multi-Source Codes [M, N, O, Y])

SINGLE INGREDIENT AGENT(S)				
Brand (generic)	GPI	Daily Quantity Limit	Quantity Equaling <50 MME/day	Age Limit
butorphanol <sup>a</sup>				
10 mg/mL nasal	65200020102050	0.25 mL	See note*	NA
spray				
Codeine				
15 mg tablet	65100020200305	6 tablets	22 tablets	≥18 years
30 mg tablet <sup>a</sup>	65100020200310	6 tablets	11 tablets	≥18 years
60 mg tablet	65100020200315	6 tablets	5 tablets	≥18 years
<b>Dilaudid (hydrom</b>	orphone) <sup>a</sup>			
2 mg tablet	65100035100310	6 tablets	5 tablets	NA
4 mg tablet	65100035100320	6 tablets	3 tablets	NA
8 mg tablet	65100035100330	6 tablets	1 tablet	NA
1 mg/mL liquid	65100035100920	48 mL	10 mL	NA
Levorphanol <sup>a</sup>				
2 mg tablet	65100040100305	4 tablets	2 tablets	NA
3 mg tablet	65100040100310	4 tablets	1 tablet	NA
Meperidine				•
50 mg tablet	65100045100305	12 tablets	10 tablets	NA
50 mg/5 mL	65100045102060	60 mL	50 mL	NA
solution				
<b>Dolophine (metha</b>	adone) <sup>a</sup>			•
5 mg tablet	65100050100305	3 tablets	3 tablets	NA
10 mg tablet	65100050100310	3 tablets	1 tablet	NA
Methadose, Metha				•
40 mg soluble	65100050107320	3 tablets	see note*	NA
tablet				
5 mg/5 mL	65100050102010	30 mL	11 mL	NA
solution				
10 mg/5 mL	65100050102015	15 mL	6 mL	NA
solution				
10 mg/mL	65100050101310	3 mL	1 mL	NA
concentrate				
Morphine sulfate				

## TARGET AGENT(S) FOR NEW TO THERAPY<sup>b</sup>

 $MN\_CSReg\_Opioids\_IR\_NTT\_QL\_ProgSum\_07-01-2024v2$ 

15		10 +	2 + - 6 1 - 1	NIA
15 mg tablet <sup>a</sup>	65100055100310	12 tablets	3 tablets	NA
30 mg tablet <sup>a</sup>	65100055100315	6 tablets	1 tablet	NA
10 mg/5 mL	65100055102065	90 mL	25 mL	NA
solution		45 1		
20 mg/5 mL solution <sup>a</sup>	65100055102070	45 mL	12 mL	NA
20 mg/mL	65100055102090	9 mL	2 mL	NA
concentrate <sup>a</sup>				
	d, Roxicodone (oxy		C an and a s	NI A
5 mg capsule <sup>a</sup>	65100075100110	12 capsules	6 capsules	NA
5 mg tablet <sup>a</sup>	65100075100310	12 tablets	6 tablets	NA
5 mg tablet	6510007510A530	12 tablets	6 tablets	NA
7.5 mg tablet	65100075100315	6 tablets	4 tablets	NA
10 mg tablet <sup>a</sup>	65100075100320	6 tablets	3 tablets	NA
15 mg tablet <sup>a</sup>	65100075100325	6 tablets	2 tablets	NA
15 mg tablet	6510007510A540	6 tablets	2 tablets	NA
20 mg tablet <sup>a</sup>	65100075100330	6 tablets	1 tablet	NA
30 mg tablet <sup>a</sup>	65100075100340	6 tablets	1 tablet	NA
30 mg tablet	6510007510A560	6 tablets	1 tablet	NA
5 mg/5 mL solution <sup>a</sup>	65100075102005	180 mL	33 mL	NA
20 mg/mL	65100075101320	9 mL	1 mL	NA
concentrate <sup>a</sup>		-		
Opana (oxymorp	hone)ª			
5 mg tablet	65100080100305	6 tablets	3 tablets	NA
10 mg tablet	65100080100310	6 tablets	1 tablet	NA
Nucynta (tapenta				
50 mg tablet	65100091100320	6 tablets	2 tablets	NA
75 mg tablet	65100091100330	6 tablets	1 tablet	NA
100 mg tablet	65100091100340	6 tablets	1 tablet	NA
Qdolo, Ultram, Tr	amadol			
25 mg tablet	65100095100310	8 tablets	10 tablets	≥18 years
50 mg tablet <sup>a</sup>	65100095100320	8 tablets	5 tablets	≥18 years
100 mg tablet <sup>a</sup>	65100095100340	4 tablets	3 tablets	≥18 years
5 mg/mL solution	65100095102005	80 mL	50 mL	≥18 years
	COMBINATION I	NGREDIENT AG	ENT(S)	
	rocodone/acetamin			
4.08/325 mg tablet	65990002020310	12 tablets	11 tablets $^{\ddagger}$	NA
6.12/325 mg	65990002020320	12 tablets	7 tablets <sup>‡</sup>	NA
tablet				_
8.16/325 mg	65990002020330	12 tablets	6 tablets <sup>‡</sup>	NA
tablet	_			
	ne (acetaminophen/			
120 mg/12 mg/5 mL solution	65991002052020	90 mL	138 mL‡	≥18 years
300 mg/15 mg tablet	65991002050310	12 tablets	22 tablets <sup>‡</sup>	≥18 years
300 mg/30 mg	65991002050315	12 tablets	11 tablets <sup>‡</sup>	≥18 years
tablet 300 mg/60 mg	65991002050320	6 tablets	5 tablets <sup>‡</sup>	≥18 years
tablet				,

MN\_CSReg\_Opioids\_IR\_NTT\_QL\_ProgSum\_07-01-2024v2

50 mg/300 mg/40 mg/30 mg capsule65991004100113 50 mg/325 mg/40 659910041001156 capsules 6 capsule11 capsules <sup>4</sup> 218 years mg/30 mg capsule218 years 218 years 218 years 218 years 218 years 218 years 218 years 218 years 220 mg/30 mg capsule11 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 218 years 220 mg/30 mg capsule11 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 218 years 220.5 mg/30 mg capsule11 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 218 years 220.5 mg/30 mg/16 capsule12 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 218 years 220.5 mg/30 mg/16 capsule12 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 218 years 225 mg/30 mg/16 capsule10 capsules 12 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 225 mg/30 mg/16 c5991702100309 c for ablets12 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 226 mg/30 mg capsule10 capsules 12 capsules <sup>1</sup> 218 years 218 years 218 years 218 years 218 years 226 mg/30 mg capsule218 years 218 years 218 years 218 years 218 years 218 years 218 years 226 mg/30 mg capsule 235 mg/30 mg c5991702100309 c f tablets10 capsules <sup>1</sup> 10 tablets <sup>1</sup> NA tablet <sup>2</sup> 218 years 218 years 210 tablets <sup>1</sup> 218 years 218 years 218 years	Fioricet w/Codeir	ne (butalbital/aceta	minophen/caff	eine/codeine)ª		
					>18 years	
capsule50 mg/325 mg/40 (sps)1004100115 (apsule)6 capsules11 capsules' (apsule)≥18 years (apsule)Fiorinal w/Codeine (butalbital/aspirin/caffeine/codeine)*50 mg/325 mg/40 (sps)10043001156 capsules11 capsules' (apsule)≥18 years (apsule)Trezix, Acetaminophen/caffeine/dihydrocodeine320.5 mg/30 (apsule)6599130305011510 capsules12 capsules' (apsule)≥18 years (apsule)325. mg/30 mg/16 (apsule)6599130305032010 tablets12 tablets² (apsule)≥18 years (apsule)Somg/325 mg/30 mg/16 (apsule)Somg/325 mg/30 mg/16 (apsule)Somg/325 mg (apsule)Somg/325 mg (apsule)Somg/320 mg (apsule)Somg/320 mg (apsule)		00001001100110	e capealee			
50mg/325mg/40 mg/30 mg capsule65991004100115 6 for a spules6 capsules 11 capsules* $\geq 18$ years mg/30 mg capsule≥18 years $\geq 18$ years $\approx 11$ capsules*≥18 years $\geq 18$ years $\geq 18$ years mg/30 mg capsuleFiorinal w/Codeine (butalbital/aspirin/caffeine/codeine)*Too mg/325 mg/40 mg/30 mg capsule65991004300115 6 for apsules11 capsules* 11 capsules* $\geq 18$ years mg/16 mg capsuleTrezix, Acetaminophen/caffeine/dihydrocodeine320.5 mg/3065991303050320 6 for apsules10 tablets 12 tablets*218 years $\geq 18$ years mg/16 mg capsuleagasuleLortab, Norco, Hydrocodone/acetaminophen5Tog/300 mg for apsule65991702100305 6 8 tablets10 tablets* 10 tablets*NA tablet*And tablet*10 mg/325 mg for apsule65991702100325 6 fablets6 tablets 6 tablets*NA tablet*NA tablet*10 mg/325 mg for apsule65991702100375 6 fablets6 tablets* 10 mg/325 mg 659917021003756 tablets 6 tablets*NA tablet*NA tablet*10 mg/200 mg 6599170210021590 mL 90 mL100 mL* NA mg/300 mg/15NA tablet*10 mg/200 mg 659917025003155 tablets 5 tabletsNA tablet*NA tablet*10 mg/200 mg 659917025003155 tablets 5 tablet						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		65991004100115	6 cansules	11 cansules <sup>‡</sup>	>18 years	
capsuleImage: capsuleImage: capsuleFiorinal w/Codeine659910043001156 capsules11 capsules <sup>±</sup> ≥18 yearsmg/30 mg capsule6599130305011510 capsules12 capsules <sup>±</sup> ≥18 yearsmg/16 mg capsule6599130305012510 capsules12 capsules <sup>±</sup> ≥18 yearsmg/16 mg capsule6599130305032010 tablets12 tablets <sup>4</sup> ≥18 yearsmg/16 mg capsule659917021003098 tablets10 tablets≥18 yearsMg/300 mg tablet*659917021003568 tablets10 tablets <sup>±</sup> NAS mg/325 mg tablet*659917021003226 tablets6 tablets <sup>±</sup> NA7.5 mg/300 mg tablet*659917021003568 tablets6 tablets <sup>±</sup> NA10 mg/300 mg tablet*659917021003756 tablets5 tablets <sup>±</sup> NA10 mg/300 mg tablet*659917021003756 tablets5 tablets <sup>±</sup> NA10 mg/300 mg tablet*659917021003756 tablets5 tablets <sup>±</sup> NA10 mg/300 mg/15 of mg/325 mg tablet*6599170210202467.5 mL74 mL <sup>±</sup> NA10 mg/300 mg/16 tablet*659917025003155 tablets10 tablets <sup>±</sup> NA10 mg/300 mg tablet*659917025003155 tablets10 tablets <sup>±</sup> NA10 mg/200 mg tablet*659917025003155 tablets10 tablets <sup>±</sup> NA10 mg/200 mg tablet*659917025003155 tablets13 tablets <sup>±</sup> NA10 mg/200 mg tablet*659917025003155 tablets		03331001100113	o capsules		=10 years	
Fiorinal w/Codeine (butalbital/aspirin/caffeine/codeine)*50 mg/325 mg/40659910043001156 capsules11 capsules <sup>1</sup> ≥18 yearsagsule10 capsules12 capsules <sup>1</sup> ≥18 years7rezix, Acetaminophen/caffeine/dihydrocodeine320.5 mg/306599130305011510 capsules12 capsules <sup>1</sup> ≥18 yearsagsule10 tablets12 tablets <sup>2</sup> ≥18 years≥18 yearsagsule10 tablets12 tablets <sup>2</sup> ≥18 yearsagsule599130305032010 tablets12 tablets <sup>2</sup> ≥18 yearsmg tablet659917021003098 tablets10 tablets <sup>2</sup> NAtablet <sup>4</sup> 559917021003226 tablets10 tablets <sup>2</sup> NAtablet <sup>4</sup> 659917021003226 tablets6 tablets <sup>4</sup> NAtablet <sup>4</sup> 10 mg/300 mg659917021003756 tablets5 tablets <sup>4</sup> NAtablet <sup>4</sup> 100 mg/325 mg659917021003756 tablets5 tablets <sup>4</sup> NAtablet <sup>4</sup> 100 mg/3256599170210201590 mL100 mL <sup>5</sup> NAtablet <sup>4</sup> 100 mg/300 mg/156599170210202467.5 mL74 mL <sup>4</sup> NAsolution659917025003155 tablets10 tablets <sup>4</sup> NAtablet <sup>4</sup> 10 tablets <sup>4</sup> 10 tablets <sup>4</sup> NANAtablet <sup>4</sup> 10 tablets <sup>4</sup> 10 tablets <sup>4</sup> NAtablet <sup>4</sup> 10 tablets <sup>4</sup> 10 tablets <sup>4</sup> NAtablet <sup>4</sup> 59917021020245 tablets10 tablets <sup>4</sup> NA10 mg/200 mg65991702500330 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>						
50 mg/325 mg/40 mg/30 mg capsule65991004300115 capsule6 capsules11 capsules* l≥18 years lTrezix, Acetamiophen/caffeine/dihytrocodeineTrezix, Acetamiophen/caffeine/dihytrocodeine320.5 mg/306599130305011510 capsules12 capsules* l≥18 years325 mg/30 mg/166599130305032010 tablets12 tablets* l≥18 yearsagain tabletLortab, Norco, Hytrocodone/acetaminophenTo tablets10 tablets*NAAdalet*NAablet*NASong/300 mg tablet*659917021003568 tablets10 tablets*NANAtablet*NAAdalet*NANAtablet*NATo mg/300 mg tablet*659917021003586 tablets6 tablets*NANAtablet*NA10 mg/300 mg tablet*659917021003756 tablets5 tablets*NAtablet*NA10 mg/300 mg 15 tablet*6599170210201590 mL100 mL*NANAtablet*NAtablet*NAtablet*NA10 mg/300 mg/15 tablet6599170210202467.5 mL74 mL*NAtablet*NA <td colsp<="" td=""><td></td><td>o (hutalhital (acnivi</td><td>in / coffeine / co</td><td>loino)a</td><td></td></td>	<td></td> <td>o (hutalhital (acnivi</td> <td>in / coffeine / co</td> <td>loino)a</td> <td></td>		o (hutalhital (acnivi	in / coffeine / co	loino)a	
mg/30 mg capsulennTrezix, Acetaminophen/caffeine/dihydrocodeine320.5 mg/30 capsule6599130305011510 capsules12 capsules* $\geq 18$ years325 mg/30 mg/16 capsule6599130305032010 tablets12 tablets* $\geq 18$ years325 mg/300 mg tablet659917021003098 tablets10 tablets*NA5 mg/300 mg tablet*659917021003568 tablets10 tablets*NA5 mg/300 mg tablet*659917021003226 tablets6 tablets*NA7.5 mg/300 mg tablet*659917021003226 tablets6 tablets*NA7.5 mg/325 mg tablet*659917021003586 tablets6 tablets*NA10 mg/300 mg tablet*659917021003756 tablets5 tablets*NA10 mg/325 mg tablet*659917021003056 tablets5 tablets*NA10 mg/325 mg tablet*659917021003756 tablets5 tablets*NA10 mg/300 mg tablet*6599170210201590 mL100 mL*NA10 mg/300 mg/15 tomg/300 mg tablet6599170210202467.5 mL74 mL*NA10 mg/200 mg tablet*659917025003155 tablets10 tablets*NA10 mg/200 mg tablet*659917025003005 tablets10 tablets*NA10 mg/200 mg tablet*659917025003155 tablets10 tablets*NA10 mg/200 mg tablet*659917025003305 tablets10 tablets*NA10 mg/200 mg tablet*659917025003305 tab					> 10	
capsuleImage: capsuleImage: capsuleTrezix, Acetaminophen/caffeine/dihydrocodeine320.5 mg/306599130305011510 capsules12 capsules*≥18 yearsmg/16 mg capsule6599130305032010 tablets12 tablets*≥18 yearsmg/addition to table the second colspan="2">tablet218 yearsLortab, Norco, Hydrocodone/acetaminophen5 mg/300 mg tablet*659917021003098 tablets10 tablets*NAAdalets10 tablets*NAAdalet*NA5 mg/300 mg tablet*659917021003226 tablets6 tablets*NAAdalet*NATo mg/325 mg tablet*659917021003756 tablets5 tablets*NA10 mg/325 mg tablet*659917021003756 tablets5 tablets*NA10 mg/325 mg tablet*659917021003756 tablets5 tablets*NA10 mg/325 mg tablet*6599170210201590 mL100 mL*NANAtablet*NAtablet*NA10 mg/300 mg tablet*6599170210202467.5 mL74 mL*NANAtablets10 tablets*NAtablet*NAtablet*NAtablet*NAtablet*NA10 m		65991004300115	6 capsules	11 capsules	≥18 years	
Trezix, Acetaminophen/caffeine/dihydrocodeine        320.5 mg/30      65991303050115      10 capsules $12 \text{ capsules}^{\pm}$ ≥18 years        325 mg/30 mg/16      65991303050320      10 tablets      12 tablets <sup>±</sup> ≥18 years        325 mg/30 mg/16      65991303050320      10 tablets      12 tablets <sup>±</sup> ≥18 years        200 mg      65991702100309      8 tablets      10 tablets <sup>±</sup> NA        25 mg/300 mg      65991702100326      8 tablets      10 tablets <sup>±</sup> NA        25 mg/300 mg      65991702100322      6 tablets      6 tablets <sup>±</sup> NA        7.5 mg/300 mg      65991702100375      6 tablets      6 tablets <sup>±</sup> NA        10 mg/300 mg      65991702100305      6 tablets      5 tablets <sup>±</sup> NA        10 mg/300 mg      65991702100305      6 tablets      5 tablets <sup>±</sup> NA        10 mg/300 mg/15      65991702100305      6 tablets      5 tablets <sup>±</sup> NA        10 mg/325 mg      65991702102024      67.5 mL      74 mL <sup>±</sup> NA        solution <sup>a</sup> 10 tablets <sup>±</sup> NA      25      tablet <sup>a</sup> NA						
320.5 mg/30      65991303050115      10 capsules      12 capsules <sup>±</sup> ≥18 years        agsule      325 mg/30 mg/16      65991303050320      10 tablets      12 tablets <sup>±</sup> ≥18 years        agsule      10 tablets      12 tablets <sup>±</sup> ≥18 years        brance      65991702100309      8 tablets      10 tablets <sup>±</sup> NA        brance      65991702100356      8 tablets      10 tablets <sup>±</sup> NA        7.5 mg/300 mg      65991702100322      6 tablets      6 tablets <sup>±</sup> NA        7.5 mg/300 mg      65991702100375      6 tablets      6 tablets <sup>±</sup> NA        10 mg/300 mg      65991702100375      6 tablets      5 tablets <sup>±</sup> NA        tablet <sup>a</sup> 0 mg/300 mg      65991702100305      6 tablets      5 tablets <sup>±</sup> NA        tablet <sup>a</sup> 10 mg/300 mg/15      65991702100305      6 tablets      5 tablets <sup>±</sup> NA        tablet <sup>a</sup> 0 mg/300 mg/15      65991702102024      67.5 mL      74 mL <sup>±</sup> NA        solution      10 mg/200 mg      65991702500330      5 tablets      10 tablets <sup>±</sup> NA        10 mg/200						
mg/16 mg capsule      mg/16 mg capsule      mg capsule      low	Trezix, Acetamino		ydrocodeine			
copsule	320.5 mg/30	65991303050115	10 capsules	12 capsules <sup>‡</sup>	≥18 years	
copsule	mg/16 mg		-	-	-	
325 mg/30 mg/16 mg tablet      65991303050320 (a construction of the second o						
Image tablet      Image tablet        Lortab, Norco, Hydrocodone/acetaminophen      5        5 mg/300 mg      65991702100309      8 tablets      10 tablets <sup>±</sup> NA        5 mg/325 mg      65991702100322      6 tablets      10 tablets <sup>±</sup> NA        7.5 mg/325 mg      65991702100322      6 tablets      6 tablets <sup>±</sup> NA        tablet <sup>a</sup> 7.5 mg/325 mg      65991702100322      6 tablets      6 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702100375      6 tablets      6 tablets <sup>±</sup> NA        10 mg/325 mg      65991702100375      6 tablets      5 tablets <sup>±</sup> NA        10 mg/325 mg      65991702100305      6 tablets      5 tablets <sup>±</sup> NA        10 mg/325 mg      65991702102015      90 mL      100 mL <sup>±</sup> NA        r5 mg/300 mg      65991702102024      67.5 mL      74 mL <sup>±</sup> NA        mg/15 mL      solution <sup>a</sup> 10 tablets <sup>±</sup> NA      tablet <sup>a</sup> NA        10 mg/200 mg      65991702500315      5 tablets      10 tablets <sup>±</sup> NA        tablet <sup>a</sup> 10 mg/200 mg      65991702500330		65991303050320	10 tablets	12 tablets <sup>‡</sup>	>18 years	
Lortab, Norco, Hydrocodone/acetaminophen      NA        5 mg/300 mg      65991702100309      8 tablets      10 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702100356      8 tablets      10 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702100322      6 tablets      6 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702100322      6 tablets      6 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702100358      6 tablets      5 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702100375      6 tablets      5 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702100305      6 tablets      5 tablets <sup>±</sup> NA        tablet <sup>a</sup> 65991702102015      90 mL      100 mL <sup>±</sup> NA        tablet <sup>a</sup> 65991702102024      67.5 mL      74 mL <sup>±</sup> NA        solution <sup>a</sup> 10 mg/300 mg/15      65991702500315      5 tablets      10 tablets <sup>±</sup> NA        tablet      65991702500320      5 tablets      10 tablets <sup>±</sup> NA        tablet      65991702500330      5 tablets      5 tablets <sup>±</sup> NA        tablet      65991702500330		03331303030320	10 (05)(05)	12 (05)(05)	=10 years	
5 mg/300 mg tablet <sup>a</sup> 65991702100309      8 tablets      10 tablets <sup>a</sup> NA        5 mg/325 mg tablet <sup>a</sup> 65991702100322      6 tablets      10 tablets <sup>a</sup> NA        7.5 mg/300 mg tablet <sup>a</sup> 65991702100322      6 tablets      6 tablets <sup>a</sup> NA        7.5 mg/325 mg tablet <sup>a</sup> 65991702100358      6 tablets      6 tablets <sup>a</sup> NA        10 mg/300 mg tablet <sup>a</sup> 65991702100375      6 tablets      5 tablets <sup>a</sup> NA        10 mg/325 mg tablet <sup>a</sup> 65991702100305      6 tablets      5 tablets <sup>a</sup> NA        10 mg/325 mg tablet <sup>a</sup> 65991702102015      90 mL      100 mL <sup>‡</sup> NA        mg/15 mL solution <sup>a</sup> 65991702102024      67.5 mL      74 mL <sup>‡</sup> NA        mg/200 mg tablet <sup>a</sup> 65991702500315      5 tablets      10 tablets <sup>‡</sup> NA        T.5 mg/200 mg tablet <sup>a</sup> 65991702500320      5 tablets      5 tablets <sup>‡</sup> NA        10 mg/200 mg tablet <sup>a</sup> 65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        10 mg/200 mg tablet <sup>a</sup> 65991702500330      5 tablets      13 tablets <sup>‡</sup> NA        2.5 mg/300 mg tablet		drocodono (acotam	inonhon			
tablet <sup>a</sup> 5 mg/325 mg tablet <sup>a</sup> 65991702100356      8 tablets      10 tablets <sup>‡</sup> NA        T.5 mg/300 mg tablet <sup>a</sup> 65991702100322      6 tablets      6 tablets <sup>‡</sup> NA        T.5 mg/325 mg tablet <sup>a</sup> 65991702100358      6 tablets      6 tablets <sup>‡</sup> NA        10 mg/300 mg tablet <sup>a</sup> 65991702100375      6 tablets      5 tablets <sup>‡</sup> NA        10 mg/325 mg tablet <sup>a</sup> 65991702100305      6 tablets      5 tablets <sup>‡</sup> NA        7.5 mg/325      65991702102015      90 mL      100 mL <sup>‡</sup> NA        rdshet <sup>a</sup> 100 mg/300 mg15      65991702102024      67.5 mL      74 mL <sup>‡</sup> NA        rdsheta      65991702500315      5 tablets      10 tablets <sup>‡</sup> NA        rdsheta      65991702500320      5 tablets      6 tablets <sup>‡</sup> NA        rablet <sup>a</sup> 65991702500330      5 tablets      10 tablets <sup>‡</sup> NA        rablet <sup>a</sup> 65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        rablet <sup>a</sup> 65991702500330      5 tablets      13 tablets <sup>‡</sup> NA <td></td> <td></td> <td></td> <td>10 tablata‡</td> <td>NA</td>				10 tablata‡	NA	
		62991702100309	8 lablels	TO lablels	NA	
tablet <sup>a</sup> Image: constraint of the second seco		65001700100056	0.1.1.1.1	40.11.1		
$\begin{array}{c cccc} 7.5 \mbox{ mg}/300 \mbox{ mg} \\ tablet^a \\ 7.5 \mbox{ mg}/325 \mbox{ mg} \\ tablet^a \\ 10 \mbox{ mg}/300 \mbox{ mg} \\ tablet^a \\ 10 \mbox{ mg}/300 \mbox{ mg} \\ tablet^a \\ 10 \mbox{ mg}/300 \mbox{ mg} \\ tablet^a \\ 10 \mbox{ mg}/325 \mbox{ mg} \\ tablet^a \\ 10 \mbox{ mg}/300 \mbox{ mg}/15 \mbox{ ms} \\ tablet \\ 10 \mbox{ mg}/300 \mbox{ mg}/15 \mbox{ ms} \\ tablet \\ 7.5 \mbox{ mg}/200 \mbox{ mg} \\ tablet \\ 7.5 \mbox{ mg}/200 \mbox{ mg} \\ tablet^a \\ 10 \mbox{ mg}/300 \mbox{ mg} \\ tab$		65991/02100356	8 tablets	10 tablets <sup>+</sup>	NA	
tablet <sup>a</sup> Image: constraint of the second seco						
7.5 mg/325 mg tablet <sup>a</sup> 65991702100358      6 tablets      6 tablets <sup>+</sup> NA        10 mg/300 mg tablet <sup>a</sup> 65991702100375      6 tablets      5 tablets <sup>+</sup> NA        10 mg/325 mg tablet <sup>a</sup> 65991702100305      6 tablets      5 tablets <sup>+</sup> NA        7.5 mg/325      65991702102015      90 mL      100 mL <sup>+</sup> NA        mg/15 mL solution <sup>a</sup> 100 mJ/15      65991702102024      67.5 mL      74 mL <sup>+</sup> NA        10 mg/300 mg/15      65991702102024      67.5 mL      74 mL <sup>+</sup> NA        10 mg/200 mg tablet <sup>a</sup> 65991702500315      5 tablets      10 tablets <sup>+</sup> NA        7.5 mg/200 mg tablet <sup>a</sup> 65991702500320      5 tablets      5 tablets <sup>+</sup> NA        10 mg/200 mg tablet <sup>a</sup> 65991702500330      5 tablets      5 tablets <sup>+</sup> NA        2.5 mg/300 mg tablet <sup>a</sup> 65990002200303      12 tablets      13 tablets <sup>+</sup> NA        2.5 mg/300 mg tablet <sup>a</sup> 65990002200308      12 tablets      6 tablets <sup>+</sup> NA        5 mg/325 mg tablet <sup>a</sup> 65990002200308      12 tablets      6 tablets <sup>+</sup> NA        5 mg/325 mg	7.5 mg/300 mg	65991702100322	6 tablets	6 tablets <sup>‡</sup>	NA	
tablet <sup>a</sup> Image: constraint of the second seco	tabletª					
tablet <sup>a</sup> Image: constraint of the second seco	7.5 ma/325 ma	65991702100358	6 tablets	6 tablets <sup>‡</sup>	NA	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		65991702100375	6 tablets	5 tablets‡	NΔ	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		03331702100373	0 tablets	J tubicts		
tablet <sup>a</sup> Image: constraint of the second seco		65001702100205	6 tablata	E tablata‡	NIA	
7.5 mg/325 mg/15 mL solution <sup>a</sup> 65991702102015 b 5991702102024 b 5991702102024      90 mL c 7.5 mL b 5991702102024 b 7.5 mL b c 74 mL <sup>‡</sup> NA        Hydrocodone/Ibuprofen      74 mL <sup>‡</sup> NA        5 mg/200 mg tablet      65991702500315 b 5 tablets      5 tablets b tablets <sup>‡</sup> NA        7.5 mg/200 mg tablet <sup>a</sup> 65991702500320 b 5 tablets      5 tablets <sup>‡</sup> NA        10 mg/200 mg tablet <sup>a</sup> 65991702500330 b 5 tablets      5 tablets <sup>‡</sup> NA        2.5 mg/300 mg tablet <sup>a</sup> 65991702500303 b 5 tablets      13 tablets <sup>‡</sup> NA        2.5 mg/300 mg tablet <sup>a</sup> 65990002200305 b 5 tablets      13 tablets <sup>‡</sup> NA        5 mg/300 mg tablet <sup>a</sup> 65990002200308 b 5 mg/325 mg tablet      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/300 mg tablet <sup>a</sup> 65990002200308 b 5 mg/325 mg tablet <sup>a</sup> 12 tablets      6 tablets <sup>‡</sup> NA        5 mg/325 mg tablet <sup>a</sup> 65990002200310 b 5 mg/325 mg tablet <sup>a</sup> 12 tablets      6 tablets <sup>‡</sup> NA        5 mg/325 mg tablet <sup>a</sup> 65990002200310 b 5 mg/325 mg tablet <sup>a</sup> 12 tablets      6 tablets <sup>‡</sup> NA		03991702100303	o lablets	5 Lablets	NA	
mg/15 mL solution <sup>a</sup> 65991702102024      67.5 mL 67.5 mL      74 mL <sup>‡</sup> NA        Hydrocodone/Iburofen		(5001700100015		400 1 +		
solution <sup>a</sup> 65991702102024      67.5 mL      74 mL <sup>‡</sup> NA        Hydrocodone/Ibuprofen      5 mg/200 mg      65991702500315      5 tablets      10 tablets <sup>‡</sup> NA        7.5 mg/200 mg      65991702500320      5 tablets      10 tablets <sup>‡</sup> NA        7.5 mg/200 mg      65991702500320      5 tablets      6 tablets <sup>‡</sup> NA        10 mg/200 mg      65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        10 mg/200 mg      65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        tablet <sup>a</sup> 65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        tablet <sup>a</sup> 65991702500330      5 tablets      NA      NA        tablet <sup>a</sup> 65991702500330      12 tablets      NA      NA        tablet <sup>a</sup> 65990002200303      12 tablets      13 tablets <sup>‡</sup> NA        tablet      65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        tablet      65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        tablet <sup>a</sup> 65990002200310      12 tablets      6 tablets <sup>‡</sup> NA </td <td></td> <td>65991/02102015</td> <td>90 mL</td> <td>100 mL⁺</td> <td>NA</td>		65991/02102015	90 mL	100 mL⁺	NA	
10 mg/300 mg/15 mL solution      65991702102024 of 7.5 mL      67.5 mL      74 mL <sup>‡</sup> NA        Hydrocodone/Iburofen        5 mg/200 mg      65991702500315 of 5991702500320      5 tablets      10 tablets <sup>‡</sup> NA        7.5 mg/200 mg      65991702500320      5 tablets      6 tablets <sup>‡</sup> NA        10 mg/200 mg      65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        10 mg/200 mg      65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        10 mg/200 mg      65991702500330      5 tablets      10 tablets <sup>‡</sup> NA        2.5 mg/300 mg      65990002200303      12 tablets      13 tablets <sup>‡</sup> NA        2.5 mg/325 mg      65990002200305      12 tablets      13 tablets <sup>‡</sup> NA        5 mg/300 mg      65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/325 mg      65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/325 mg      65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/300 mg      65990002200320      8 tablets      4 tablets <sup>‡</sup> NA						
mL solution      Image: ml solu						
Hydrocodone/Ibuprofen5 mg/200 mg tablet659917025003155 tablets10 tablets $^{\ddagger}$ NA7.5 mg/200 mg tableta659917025003205 tablets6 tablets $^{\ddagger}$ NA10 mg/200 mg tableta659917025003305 tablets5 tabletsNA10 mg/200 mg tableta659917025003305 tablets5 tabletsNA2.5 mg/300 mg tableta6599000220030312 tablets13 tablets $^{\ddagger}$ NA2.5 mg/325 mg tableta6599000220030512 tablets13 tablets $^{\ddagger}$ NA5 mg/300 mg tablet6599000220030812 tablets6 tablets $^{\ddagger}$ NA5 mg/325 mg tableta6599000220031012 tablets6 tablets $^{\ddagger}$ NA7.5 mg/300 mg tableta6599000220031012 tablets6 tablets $^{\ddagger}$ NA7.5 mg/300 mg tableta659900022003258 tablets4 tablets $^{\ddagger}$ NA	10 mg/300 mg/15	65991702102024	67.5 mL	74 mL‡	NA	
Hydrocodone/Ibuprofen5 mg/200 mg tablet659917025003155 tablets10 tablets $^{\ddagger}$ NA7.5 mg/200 mg tableta659917025003205 tablets6 tablets $^{\ddagger}$ NA10 mg/200 mg tableta659917025003305 tablets5 tabletsNA10 mg/200 mg tableta659917025003305 tablets5 tabletsNA2.5 mg/300 mg tableta6599000220030312 tablets13 tablets $^{\ddagger}$ NA2.5 mg/325 mg tableta6599000220030512 tablets13 tablets $^{\ddagger}$ NA5 mg/300 mg tablet6599000220030812 tablets6 tablets $^{\ddagger}$ NA5 mg/325 mg tableta6599000220031012 tablets6 tablets $^{\ddagger}$ NA7.5 mg/300 mg tableta6599000220031012 tablets6 tablets $^{\ddagger}$ NA7.5 mg/300 mg tableta659900022003258 tablets4 tablets $^{\ddagger}$ NA	mL solution					
5 mg/200 mg tablet      65991702500315      5 tablets      10 tablets <sup>‡</sup> NA        7.5 mg/200 mg tablet <sup>a</sup> 65991702500320      5 tablets      6 tablets <sup>‡</sup> NA        10 mg/200 mg tablet <sup>a</sup> 65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        10 mg/200 mg tablet <sup>a</sup> 65991702500330      5 tablets      5 tablets <sup>‡</sup> NA        2.5 mg/300 mg tablet <sup>a</sup> 65990002200303      12 tablets      13 tablets <sup>‡</sup> NA        2.5 mg/325 mg tablet <sup>a</sup> 65990002200305      12 tablets      13 tablets <sup>‡</sup> NA        5 mg/300 mg tablet <sup>a</sup> 65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/300 mg tablet <sup>a</sup> 65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        7.5 mg/300 mg      65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        7.5 mg/300 mg      65990002200325      8 tablets      4 tablets <sup>‡</sup> NA		profen		1	1	
tabletImage: constraint of the sector of the se			5 tablets	10 tablets <sup>‡</sup>	NΔ	
7.5 mg/200 mg tableta659917025003205 tablets6 tablets‡NA10 mg/200 mg tableta659917025003305 tablets5 tablets‡NAPercocet, Prolate, Oxycodone/acetaminophen, Nalocet, Primlev2.5 mg/300 mg tablet6599000220030312 tablets13 tablets‡NA2.5 mg/325 mg tableta6599000220030512 tablets13 tablets‡NA5 mg/300 mg tableta6599000220030812 tablets6 tablets‡NA7.5 mg/300 mg tableta6599000220031012 tablets6 tablets‡NA7.5 mg/300 mg tableta659900022003258 tablets4 tablets‡NA		03331702300313	5 tablets	10 (05)(05)	147.1	
tabletaImage: constraint of tabletaImage: constraint of tabletaImage: constraint of tableta10 mg/200 mg tableta659917025003305 tablets5 tablets*NAPercocet, Prolate, Oxycodone/acetaminophen, Nalocet, Primlev2.5 mg/300 mg tablet6599000220030312 tablets13 tablets*NA2.5 mg/325 mg tableta6599000220030512 tablets13 tablets*NA5 mg/300 mg tablet6599000220030812 tablets6 tablets*NA5 mg/325 mg tablet6599000220031012 tablets6 tablets*NA7.5 mg/300 mg659900022003258 tablets4 tablets*NA		65001702500220	E tablata	6 tablata‡	NIA	
10 mg/200 mg tableta659917025003305 tablets5 tablets*NAPercocet, Prolate, Oxycodone/acetaminophen, Nalocet, Primlev2.5 mg/300 mg tablet6599000220030312 tablets13 tablets*NA2.5 mg/325 mg tableta6599000220030512 tablets13 tablets*NA5 mg/325 mg tablet6599000220030812 tablets6 tablets*NA5 mg/300 mg tablet6599000220030812 tablets6 tablets*NA7.5 mg/300 mg6599000220031012 tablets6 tablets*NA7.5 mg/300 mg659900022003258 tablets4 tablets*NA		03991702300320	5 lablels	o lablets	NA	
tablet <sup>a</sup> Oxycodone/acetaminophen, Nalocet, Primlev        2.5 mg/300 mg tablet      65990002200303      12 tablets      13 tablets <sup>‡</sup> NA        2.5 mg/325 mg tablet <sup>a</sup> 65990002200305      12 tablets      13 tablets <sup>‡</sup> NA        5 mg/300 mg tablet      65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/300 mg tablet      65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/325 mg tablet      65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        7 5 mg/300 mg      65990002200325      8 tablets      4 tablets <sup>‡</sup> NA		65001702500220	<u> </u>	<b>F</b> +		
Percocet, Prolate, Oxycodone/acetaminophen, Nalocet, Primlev        2.5 mg/300 mg tablet      65990002200303      12 tablets      13 tablets <sup>‡</sup> NA        2.5 mg/325 mg tablet <sup>a</sup> 65990002200305      12 tablets      13 tablets <sup>‡</sup> NA        5 mg/300 mg tablet      65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/300 mg tablet      65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/325 mg tablet <sup>a</sup> 65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        7.5 mg/300 mg      65990002200325      8 tablets      4 tablets <sup>‡</sup> NA		65991/02500330	5 tablets	5 tablets <sup>+</sup>	NA	
2.5 mg/300 mg tablet    65990002200303    12 tablets    13 tablets <sup>‡</sup> NA      2.5 mg/325 mg tablet <sup>a</sup> 65990002200305    12 tablets    13 tablets <sup>‡</sup> NA      5 mg/300 mg tablet    65990002200308    12 tablets    6 tablets <sup>‡</sup> NA      5 mg/300 mg tablet    65990002200308    12 tablets    6 tablets <sup>‡</sup> NA      7 mg/325 mg tablet <sup>a</sup> 65990002200310    12 tablets    6 tablets <sup>‡</sup> NA      7.5 mg/300 mg    65990002200325    8 tablets    4 tablets <sup>‡</sup> NA						
tablet      Image: constraint of tablet      Image: constraint o						
2.5 mg/325 mg tablet <sup>a</sup> 65990002200305    12 tablets    13 tablets <sup>‡</sup> NA      5 mg/300 mg tablet    65990002200308    12 tablets    6 tablets <sup>‡</sup> NA      5 mg/325 mg tablet <sup>a</sup> 65990002200310    12 tablets    6 tablets <sup>‡</sup> NA      7.5 mg/300 mg    65990002200325    8 tablets    4 tablets <sup>‡</sup> NA	2.5 mg/300 mg	65990002200303	12 tablets	13 tablets <sup>‡</sup>	NA	
tableta    Image: constraint of tableta    Image: constraint of tableta    Image: constraint of tableta      5 mg/300 mg tablet    65990002200308    12 tablets    6 tablets <sup>‡</sup> NA      5 mg/325 mg tableta    65990002200310    12 tablets    6 tablets <sup>‡</sup> NA      7.5 mg/300 mg    65990002200325    8 tablets    4 tablets <sup>‡</sup> NA	tablet					
tableta    Image: constraint of tableta    Image: constraint of tableta    Image: constraint of tableta      5 mg/300 mg tablet    65990002200308    12 tablets    6 tablets <sup>‡</sup> NA      5 mg/325 mg tableta    65990002200310    12 tablets    6 tablets <sup>‡</sup> NA      7.5 mg/300 mg    65990002200325    8 tablets    4 tablets <sup>‡</sup> NA	2.5 mg/325 mg	65990002200305	12 tablets	13 tablets <sup>‡</sup>	NA	
5 mg/300 mg tablet      65990002200308      12 tablets      6 tablets <sup>‡</sup> NA        5 mg/325 mg tablet <sup>a</sup> 65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        7.5 mg/300 mg      65990002200325      8 tablets      4 tablets <sup>‡</sup> NA	<b>.</b>					
tablet           5 mg/325 mg      65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        tablet <sup>a</sup> 7.5 mg/300 mg      65990002200325      8 tablets      4 tablets <sup>‡</sup> NA		65990002200308	12 tablets	6 tablets <sup>‡</sup>	NΔ	
5 mg/325 mg      65990002200310      12 tablets      6 tablets <sup>‡</sup> NA        tablet <sup>a</sup> 7.5 mg/300 mg      65990002200325      8 tablets      4 tablets <sup>‡</sup> NA		33330002200300				
tablet <sup>a</sup> fill      fill        7.5 mg/300 mg      65990002200325      8 tablets      4 tablets <sup>‡</sup> NA		650000000000000000000000000000000000000	12 tablata	6 tablata‡	NIA	
7.5 mg/300 mg 65990002200325 8 tablets 4 tablets <sup>‡</sup> NA		02330005500310	12 ladiets	o ladiets	NA	
5, 5			<b>.</b>	<b>.</b> +		
tablet		65990002200325	8 tablets	4 tablets <sup>∓</sup>	NA	
	tablet					

MN\_CSReg\_Opioids\_IR\_NTT\_QL\_ProgSum\_07-01-2024v2

Page 10 of 15

7.5 mg/325 mg tablet <sup>a</sup>	65990002200327	8 tablets	4 tablets <sup>‡</sup>	NA
10 mg/300 mg tablet	65990002200333	6 tablets	3 tablets <sup>‡</sup>	NA
10 mg/325 mg tablet <sup>a</sup>	65990002200335	6 tablets	3 tablets <sup>‡</sup>	NA
10 mg/300 mg/5 mL solution	65990002202020	30 mL	15 mL <sup>‡</sup>	NA
5 mg/325 mg/5 mL solution	65990002202005	60 mL	30 mL <sup>‡</sup>	NA
Oxycodone/Ibup	rofen			
5 mg/400 mg tablet	65990002260320	4 tablets	6 tablets <sup>‡</sup>	NA
pentazocine/nalo	xone <sup>a</sup>			
50 mg/0.5 mg tablet	65200040300310	12 tablets	2 tablets <sup>‡</sup>	NA
Seglentis (celeco	xib/tramadol)			
56 mg/44 mg tablet	65995002100320	4 tablets	13 tablets <sup>‡</sup>	≥18 years
Ultracet (tramado	ol/acetaminophen) <sup>a</sup>			
37.5 mg/325 mg tablet	65995002200320	8 tablets	7 tablets	≥18 years

a - generic available

b - all target agents are subject to a  $\leq$  7 days of therapy and <50 morphine milligram equivalents per day if no prior opioid or oncology claims are found in the past 120 days

\* - product minimum dosage strength surpasses 50 MME

 + - quantity for being under 50 MME per day may exceed dosing limit of other ingredients in the combination product

## PRIOR AUTHORIZATION CRITERIA FOR APPROVAL

Target Agent(s) will be approved when ONE of the following is met:

- 1. The request exceeds the 7 day supply limit and/or the 50 morphine milligram equivalent per day limit AND ALL of the following:
  - A. If the requested agent contains acetaminophen, then the requested dose of acetaminophen does NOT exceed 4 g/day

## AND

- B. If the requested agent contains tramadol, dihydrocodeine, OR codeine, then ONE of the following:
  - The patient is 12 to less than 18 years of age AND the requested agent will NOT be used for post-operative pain management following a tonsillectomy and/or adenoidectomy

## OR

ii. The patient is 18 years of age or over

## AND

- C. ONE of the following:
  - i. The requested quantity (dose) does NOT exceed the program daily quantity limit AND ONE of the following:
    - a. There is information that the patient is NOT new to opioid therapy in the past 120 days
       OR
    - b. The prescriber states the patient is NOT new to opioid therapy AND is at risk if therapy is changed
       OR

MN\_CSReg\_Opioids\_IR\_NTT\_QL\_ProgSum\_07-01-2024v2

c. The patient has a claim for an oncology agent in the past 120 days

## OR

- d. BOTH of the following:
  - 1. ONE of the following:
    - A. The patient has a diagnosis of chronic cancer pain due to an active malignancy
      OR
    - B. The patient is eligible for hospice OR palliative care

## OR

C. The patient has a diagnosis of sickle cell disease

## OR

- D. The patient is undergoing treatment of noncancer pain and ALL of the following:
  - The prescriber has provided information in support of use of immediate-release single or combination opioids for an extended duration (>7 days) and/or greater than a 50 morphine milligram equivalents (MME) per day

## AND

- ii. A formal, consultative evaluation which includes BOTH of the following was conducted:
  - a. Diagnosis AND
  - A complete medical history which includes previous and current pharmacological and non-pharmacological therapy

## AND

iii. A patient-specific pain management plan is on file for the patient

## AND

iv. The prescriber has reviewed the patient's records in the state's prescribing drug monitoring program (PDMP) AND has determined that the opioid dosage and combinations within the patient's records do NOT indicate the patient is at high risk for overdose

## AND

- 2. ONE of the following:
  - A. The patient is not concurrently using buprenorphine or buprenorphine/naloxone agent for opioid dependence treatment OR

Effective: 07/01/2024

B. The prescriber has provided information in support of use of opioids with buprenorphine or buprenorphine/naloxone agent for opioid dependence treatment

#### OR

ii. The requested quantity (dose) exceeds the program daily quantity limit AND ALL of the following:

a. ONE of the following:

 There is information that the patient is NOT new to opioid therapy in the past 120 days

#### OR

- The prescriber states the patient is NOT new to opioid therapy AND is at risk if therapy is changed OR
- 3. The patient has a claim for an oncology agent in the past 120 days

#### OR

 The prescriber has provided information in support of use of immediate-release single or combination opioids for an extended duration (>7 days) and/or greater than a 50 morphine milligram equivalents (MME) per day

## AND

- b. ONE of the following:
  - The patient has a diagnosis of chronic cancer pain due to an active malignancy OR
  - The patient is eligible for hospice OR palliative care OR
  - The patient has a diagnosis of sickle cell disease OR
  - 4. The patient is undergoing treatment of non-cancer pain and ALL of the following:
    - A. A formal, consultative evaluation which includes BOTH of the following was conducted:

## i. Diagnosis

## AND

 A complete medical history which includes previous and current pharmacological and nonpharmacological therapy

## AND

B. A patient-specific pain management plan is on file for the patient

## AND

C. The prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) **AND** has determined that the opioid dosages and combinations within the patient's records do

NOT indicate the patient is at high risk for overdose

#### AND

- c. ONE of the following:
  - The patient is not concurrently using buprenorphine or buprenorphine/naloxone agent for opioid dependence treatment
     OR
  - 2. The prescriber has provided information in support of use of opioids with buprenorphine or buprenorphine/naloxone agent for opioid dependence treatment

#### AND

d. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit

AND

e. The prescriber has provided information in support of therapy with a higher dose for the requested indication

#### OR

- 2. The request does NOT exceed the 7 day supply limit nor the 50 morphine milligram equivalent per day limit; but the requested dose exceeds the program quantity daily limit AND ALL of the following:
  - A. ONE of the following:
    - i. The patient has a diagnosis of chronic cancer pain due to an active malignancy
      - OR
    - ii. The patient is eligible for hospice OR palliative care **OR**
    - iii. The patient has a diagnosis of sickle cell disease **OR**
    - iv. The patient is undergoing treatment of non-cancer pain and ALL of the following:
      - a. A formal, consultative evaluation which includes BOTH of the following was conducted:
        - 1. Diagnosis

## AND

2. A complete medical history which includes previous and current pharmacological and nonpharmacological therapy

## AND

b. A patient-specific pain management plan is on file for the patient

## AND

c. The prescriber has reviewed the patient's records in the state's prescription drug monitoring program (PDMP) **AND** has determined that the opioid dosages and combinations within the patient's records do NOT indicate the patient is at high risk for overdose

#### AND

B. ONE of the following:

MN\_CSReg\_Opioids\_IR\_NTT\_QL\_ProgSum\_07-01-2024v2

- The patient is not concurrently using buprenorphine or buprenorphine/naloxone agent for opioid dependence treatment OR
- ii. The prescriber has provided information in support of use of opioids with buprenorphine or buprenorphine/naloxone agent for opioid dependence treatment

## AND

C. If the requested agent contains acetaminophen, then the requested dose of acetaminophen does NOT exceed 4 g/day

## AND

- D. If the requested agent contains tramadol, dihydrocodeine, OR codeine, then ONE of the following:
  - The patient is 12 to less than 18 years of age AND the requested agent will NOT be used for post-operative pain management following a tonsillectomy and/or adenoidectomy OR
  - ii. The patient is 18 years of age or over

## AND

- E. BOTH of the following:
  - i. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit

## AND

ii. The prescriber has provided information in support of therapy with a higher dose for the requested indication

## OR

- 3. The request does NOT exceed the 7 day supply limit nor the 50 morphine milligram equivalent per day limit nor the program quantity daily limit AND the requested agent contains tramadol, dihydrocodeine, OR codeine, then ONE of the following:
  - A. The patient is 12 to less than 18 years of age AND the requested agent will NOT be used for post-operative pain management following a tonsillectomy and/or adenoidectomy

# OR

B. The patient is 18 years of age or over

## Length of Approval: 6 months